PT - JOURNAL ARTICLE AU - Brooimans, R A AU - van den Berg, A J AU - Rijkers, G T AU - Sanders, L A AU - van Amstel, J K AU - Tilanus, M G AU - Grubben, M J AU - Zegers, B J TI - Identification of novel Bruton's tyrosine kinase mutations in 10 unrelated subjects with X linked agammaglobulinaemia. AID - 10.1136/jmg.34.6.484 DP - 1997 Jun 01 TA - Journal of Medical Genetics PG - 484--488 VI - 34 IP - 6 4099 - http://jmg.bmj.com/content/34/6/484.short 4100 - http://jmg.bmj.com/content/34/6/484.full SO - J Med Genet1997 Jun 01; 34 AB - Mutations of the Bruton's tyrosine kinase (Btk) gene cause X linked agammaglobulinaemia (XLA). This inherited immunodeficiency disease causes an arrest in B cell differentiation of pre-B cells to mature B cells. In this study we report the characterisation of mutations in the Btk gene in 10 unrelated XLA families. The screening approach we used was based on reverse transcriptase PCR and direct cycle sequencing of the amplified products followed by analysis of the observed mutations at the level of genomic DNA. The single strand confirmation polymorphism (SSCP) technique was used for assessment of the carriers in some of these families. Various mutations throughout the coding gene were observed, including missense and nonsense mutations, a deletion, and several splicing defects. None of the mutations except one has been previously described. There were three point mutations resulting in a single amino acid substitution. One of these missense mutations was observed in a conserved region of the PH domain, the other two were found in the src homology domain 2 that is involved in phosphotyrosyl peptide binding. Two mutations were single base pair substitutions resulting in premature stop codons. In four patients abnormal Btk transcripts were found that were the result of aberrant splicing. One small deletion was observed causing a frameshift and a secondary premature termination signal. Characterisation of the mutations responsible for XLA allowed us to diagnose the disease conclusively and identify the phenotypically normal female carriers.